U.S. Real-World Evidence (RWE) Solutions Market by Component, Application (Market Access & Reimbursement, Drug Development & Approvals), End User - Forecast to 2036

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (EMR/EHR/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Integrated Datasets)], Application (Market Access & Reimbursement, Drug Development & Approvals), End User - Forecast to 2036

According to the research report titled, 'U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (EMR/EHR/Clinical Data, Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Integrated Datasets)], Application (Market Access & Reimbursement, Drug Development & Approvals), End User - Forecast to 2036,' the U.S. real-world evidence (RWE) solutions market is expected to reach approximately USD 3.52 billion by 2036 from USD 1.46 billion in 2026, at a CAGR of 9.2% during the forecast period (2026-2036). The report provides an in-depth analysis of the U.S. RWE solutions market, emphasizing current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of the U.S. RWE solutions market is driven by rapidly growing big data in healthcare, the shift from volume-based to value-based care, the rising focus toward personalized healthcare and precision medicine, and increasing regulatory acceptance of RWE by the U.S. Food and Drug Administration (FDA). Furthermore, the rising adoption of artificial intelligence and machine learning in RWD analysis and the growing integration of genomic data into RWE datasets are expected to offer significant growth opportunities for players operating in the U.S. RWE solutions market.

Market Segmentation

The U.S. RWE solutions market is segmented by component (datasets and consulting & analytics), application (market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals, and clinical and regulatory decision-making), and end user (pharmaceutical, biotechnology & medical device companies, healthcare payers, healthcare providers, and others). The study also evaluates industry competitors and analyzes the market at the country level.

Based on Component

By component, the datasets segment holds the largest share of the overall U.S. RWE solutions market in 2026. This dominance is primarily driven by the extensive availability of structured real-world healthcare datasets, including medical claims data from commercial insurers, Medicare, and Medicaid; EHR data from large integrated health systems; and specialty pharmacy data. Datasets represent the foundational element for evidence generation. However, the consulting and analytics segment is expected to witness the fastest CAGR during the forecast period. This growth is attributed to the increasing complexity of RWD curation, the rising need for advanced statistical modeling and machine learning techniques to extract insights from unstructured clinical text, and the growing demand for regulatory-grade RWE study design and reporting services.

Based on Application

By application, the market access & reimbursement/coverage decisions segment holds the largest share of the overall U.S. RWE solutions market in 2026. This dominance is attributed to the increasing pressure on life sciences companies to demonstrate the value and cost-effectiveness of their products to payers, the growing adoption of value-based contracting, and the impact of the Inflation Reduction Act (2022) on Medicare price negotiations. However, the drug development & approvals segment is expected to witness the fastest CAGR during the forecast period. This growth is driven by the expanding regulatory acceptance of RWE by the FDA for new indication approvals, label expansions, and post-approval study commitments, as well as the increasing use of RWE in oncology, neurology, and immunology for evidence generation in rare disease populations.

Based on End User

By end user, the pharmaceutical, biotechnology & medical device companies segment holds the largest share of the overall U.S. RWE solutions market in 2026. This segment represents the primary customer for RWE solutions, utilizing them across the product life cycle from R&D and regulatory submissions to market access and post-market safety surveillance. Healthcare payers also represent a significant end-user segment, utilizing RWE for formulary decision-making, population health management, and evaluating the real-world performance of high-cost therapies. Healthcare providers and research institutions are increasingly adopting RWE platforms to support clinical decision-making and academic research.

Geographic Analysis

The U.S. is the largest and most advanced market for real-world evidence solutions globally. The market growth in the U.S. is supported by the extensive digitalization of healthcare records, a robust ecosystem of RWD aggregators, and the presence of leading life sciences companies. The regulatory environment in the U.S., shaped by the 21st Century Cures Act and subsequent FDA guidances, provides a clear framework for the use of RWE in regulatory decision-making. The increasing focus on health equity and the inclusion of diverse real-world populations in clinical evidence are further driving the demand for comprehensive RWD sources across the country. The key companies operating in the U.S. market are IQVIA Holdings Inc., Optum, Inc., Elevance Health, Inc., and Oracle Corporation, among others.

Key Players

The key players operating in the U.S. real-world evidence solutions market are IQVIA Holdings Inc. (U.S.), Optum, Inc. (a UnitedHealth Group company) (U.S.), Elevance Health, Inc. (U.S.), ICON plc (Ireland), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), SAS Institute Inc. (U.S.), PPD (a Thermo Fisher Scientific company) (U.S.), Flatiron Health, Inc. (U.S.), Aetion, Inc. (U.S.), TriNetX, LLC (U.S.), Merative (U.S.), Medidata Solutions (a Dassault Systemes company) (U.S.), and Fortrea Holdings Inc. (U.S.).

Key Questions Answered in the Report-

• What is the current revenue generated by the U.S. RWE solutions market?
• At what rate is the U.S. RWE solutions market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the U.S. RWE solutions market?
• What are the major factors impacting the growth of this market in the U.S.? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of component, application, and end user are expected to create major traction for the technology providers in this market?
• What are the key regulatory trends impacting the U.S. RWE solutions market? How is the FDA's Advancing RWE Program influencing market dynamics?
• Who are the major players in the U.S. RWE solutions market? What are their specific technology and service offerings in this market?
• What are the recent strategic developments in the U.S. RWE solutions market? What are the impacts of these strategic developments on the market?

Scope of the Report:

U.S. RWE Solutions Market Assessment -- by Component

• Datasets
  • Disparate Datasets

EMR/EHR/Clinical Data

Claims & Billing Data

Pharmacy Data

Product/Disease Registries Data

Other Disparate Datasets

• Integrated Datasets
• Consulting and Analytics

U.S. RWE Solutions Market Assessment -- by Application

• Market Access & Reimbursement/Coverage Decisions
• Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
• Post-Market Surveillance
• Medical Device Development & Approvals
• Clinical and Regulatory Decision-Making

U.S. RWE Solutions Market Assessment -- by End User

• Pharmaceutical, Biotechnology & Medical Device Companies
• Healthcare Payers
• Healthcare Providers
• Other End Users